Dashboard
Manage Tickers

ZVRA ZEVRA THERAPEUTICS, INC.

Nasdaq kempharm.com


$ 10.01 $ -0.11 (-1.09 %)    

Tuesday, 04-Nov-2025 10:29:23 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 626.14 $ 2.95 (0.47 %)
DIA $ 472.41 $ 2.05 (0.44 %)
SPY $ 679.21 $ 3.08 (0.46 %)
TLT $ 90.02 $ 0.23 (0.26 %)
GLD $ 363.23 $ -0.34 (-0.09 %)
$ 10.21
$ 10.12
$ 9.99 x 90
$ 10.02 x 256
$ 9.83 - $ 10.12
$ 6.19 - $ 13.16
2,881,915
na
573.14M
$ 4.26
$ 216.77
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-12-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-22-2017 03-31-2017 10-Q
35 03-10-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-16-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

top-stocks-with-earnings-this-week-joby-ionq-amd-and-more
Top Stocks With Earnings This Week: Joby, ...
11/03/2025 14:14:07

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket
Why PepGen Shares Are Trading Higher By 11...
09/25/2025 10:11:08

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

zevra-therapeutics-presents-several-posters-highlighting-new-data-on-miplyffa-for-treatment-of-niemann-pick-disease-type-c-at-iciem
Zevra Therapeutics Presents Several Poster...
09/04/2025 11:33:27

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 21:06:23

zevra-therapeutics-to-present-four-posters-on-miplyffa-at-iciem-2025
Zevra Therapeutics To Present Four Posters...
08/28/2025 11:32:02

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

watching-zevra-therapeutics-traders-circulate-unconfirmed-rumor-suggesting-the-co-is-seeing-a-buyout-proposal
Watching Zevra Therapeutics; Traders Circu...
08/21/2025 14:42:47

crude-oil-down-1-performance-food-group-earnings-top-views
Crude Oil Down 1%; Performance Food Group ...
08/13/2025 19:19:46

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

jmp-securities-maintains-market-outperform-on-zevra-therapeutics-lowers-price-target-to-18
JMP Securities Maintains Market Outperform...
08/13/2025 14:27:37

JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the pr...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 12:08:29

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/12/2025 21:07:08

zevra-therapeutics-q2-eps-124-beats-113-estimate-sales-2590m-beat-2249m-estimate
Zevra Therapeutics Q2 EPS $1.24 Beats $1.1...
08/12/2025 20:09:22

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1...

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

a-look-at-zevra-therapeuticss-upcoming-earnings-report
A Look at Zevra Therapeutics's Upcoming Ea...
08/11/2025 15:03:31

zevra-therapeutics-has-submitted-a-marketing-authorization-application-to-the-european-medicines-agency-for-the-evaluation-of-arimoclomol-for-niemann-pick-disease-type-c
Zevra Therapeutics Has Submitted A Marketi...
07/28/2025 10:06:06

The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is gr...

zevra-therapeutics-to-present-three-posters-on-miplyffa-and-one-on-olpruva-annual-sergg-2025
Zevra Therapeutics To Present Three Poster...
07/18/2025 11:32:07

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

zevra-therapeutics-reports-sustained-5-year-efficacy-of-miplyffa-in-treating-npc-as-published-in-molecular-genetics-and-metabolism
Zevra Therapeutics Reports Sustained 5-Yea...
07/16/2025 11:33:49

zevra-showcases-miplyffa-data-at-nnpdf-conference-highlights-long-term-efficacy-mechanism-in-treating-niemann-pick-type-c
Zevra Showcases MIPLYFFA Data At NNPDF Con...
07/11/2025 11:32:34

cantor-fitzgerald-maintains-overweight-on-zevra-therapeutics-raises-price-target-to-29
Cantor Fitzgerald Maintains Overweight on ...
07/10/2025 11:41:52

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price t...

how-zevras-miplyffa-could-transform-investment-strategies
How Zevra's Miplyffa Could Transform Inves...
07/02/2025 19:59:44

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy ratin...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION